GLP-1 receptor agonists begin exerting physiological effects at different rates depending on the specific medication, though the timeline for clinically meaningful outcomes varies by therapeutic goal
Their oral bacterial ecology already favors cavity-producing organisms, and reduced saliva removes one of the few remaining protective barriers
The FDA issued a warning to consumers about using compounded versions of GLP-1 medications
Jos Morales, MD, a vascular neurologist and neurointerventional surgeon at Providence Saint Johns Health Center in Santa Monica, CA, also not involved in this review, told MNT that microglias effect on the neurovascular unit has been associated with dementia. He suggested that: [GLP-1 drugs] could potentially modulate inflammation to reduce the propensity for developing dementias such as Alzheimers disease, particularly in the setting of metabolic syndrome. Morales also explained that in people who have glycemia or type 2 diabetes, the inflammation of the blood-brain barrier can lead to progressive damage to the brain over longer periods. He noted that trials that combine neuroimaging techniques that measure the blood-brain barrier and GLP-1 treatment are needed and could prove that these drugs have neuroprotective benefits.

Meanwhile, as it rings in a strategic transformation, including a revamp of product offerings, such as a new line of collagen products, and distributor-compensation plans, LifeVantage is also in search of fresh scientific talent
The Wikipedia overview of Retatrutide provides additional trial context